Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28246648 | 0.84 | MEN1 (0.52) | FAAHMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL2636547 | 0.84 | MEN1 (0.68) | FAAHMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL1867074 | 0.84 | CCR3 (0.52) | FAAHMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL27803883 | 0.84 | TACR3 (0.51) | FAAHMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL19873074 | 0.84 | MEN1 (0.61) | FAAHMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL23365213 | 0.84 | CYP2C9 (0.54) | FAAHMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL1364179 | 0.81 | FAAH (0.47) | FAAHMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL6397917 | 0.81 | MGLL (0.66) | FAAH | |
| SCHEMBL2933305 | 0.81 | CYP2C9 (0.54) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL758717 | 0.81 | ENPP2 (0.44) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | FAAH 550/4885MEN1 4641/4885KMT2A 2066/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | FAAH 550/4885MEN1 4641/4885KMT2A 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.